SCHEMBL12868340

SCHEMBL12868340

CCOC(=O)N1CCc2[nH]c3ccc(Cl)cc3c2C1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.79
PABPC1 P11940 1/20 0.79
ATM Q13315 1/20 0.79
SMN1; SMN2 Q16637 1/20 0.79
BAZ2B Q9UIF8 12/20 0.73
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
MAPT P10636 3/20 0.59
ALOX15 P16050 2/20 0.59
MAPK1 P28482 2/20 0.59
GAA P10253 2/20 0.59
CASP1 P29466 2/20 0.59
CASP7 P55210 2/20 0.59
ALOX12 P18054 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
ALDH1A1 P00352 2/20 0.57
KDM4E B2RXH2 1/20 0.57
POLB P06746 1/20 0.57
HSD17B10 Q99714 1/20 0.57
NPC1 O15118 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316982 0.91 LMNA (0.65) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL11756284 0.90 LMNA (0.63) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL407460 0.88 LMNA (1.00) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL10777655 0.86 SMN1; SMN2 (0.79) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL764099 0.86 LMNA (0.79) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL2189766 0.86 BAZ2B (0.63) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL12868564 0.85 LMNA (0.78) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL21114757 0.85 BAZ2B (0.71) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL541660 0.85 LMNA (0.78) LMNAPABPC1ATMSMN1; SMN2BAZ2B
SCHEMBL940424 0.83 LMNA (0.74) LMNAPABPC1ATMSMN1; SMN2BAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046368-A1 LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF IVASHCHENKO ANDREY ALEXANDROVICH 2011-02-24 US disclosed
US-20110046368-A1 LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF IVASHCHENKO ANDREY ALEXANDROVICH 2011-02-24 US disclosed
EP-2184064-A2 LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF Alla Chem, LLC. (US) 2010-05-12 EP disclosed
WO-2008060190-A2 LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF ALLA CHEM, LLC (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046368-A1 LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF HTR6, HTR1A, HTR3B LMNA 2568/4885PABPC1 3818/4885ATM 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.